These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084 [TBL] [Abstract][Full Text] [Related]
5. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related]
6. The Tumor Suppressor BRCA1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers. Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066 [TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435 [TBL] [Abstract][Full Text] [Related]
8. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Batalini F; Gulhan DC; Mao V; Tran A; Polak M; Xiong N; Tayob N; Tung NM; Winer EP; Mayer EL; Knappskog S; Lønning PE; Matulonis UA; Konstantinopoulos PA; Solit DB; Won H; Eikesdal HP; Park PJ; Wulf GM Clin Cancer Res; 2022 Nov; 28(21):4714-4723. PubMed ID: 36048535 [TBL] [Abstract][Full Text] [Related]
9. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839 [TBL] [Abstract][Full Text] [Related]
10. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Pothuri B Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965 [TBL] [Abstract][Full Text] [Related]
11. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086 [TBL] [Abstract][Full Text] [Related]
16. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305 [TBL] [Abstract][Full Text] [Related]
17. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471 [TBL] [Abstract][Full Text] [Related]
18. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers. Tian T; Shan L; Yang W; Zhou X; Shui R Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969 [TBL] [Abstract][Full Text] [Related]
20. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]